The Eisai Partnership is the Kiss of Death
.
1. Zonegrame: purchased from Elan for $200 million cash + all the market personnel + sales people
Result: total sales for Eisai from Zonegrame is about $240 million. Eisai ended up with unproductive employees and eventually they after consumed Eisai, they are gone. In addition, Eisai had to settle a lawsuit wit DOJ for Eisai's illegal marketing activities for $11 million. I would say Eisai breaks even on this deal if you only count the capital spending
2. Fragmin: Pfizer sold this dog to Eisai years ago. The Contract states Eisai has to net sale $100 million worth of Fragmin no matter what market condition is. Otherwise, Eisai pays up to $100 million to Pfizer. Fragmin has no had a $100 net sales.
Result: This is a loss for Eisai
3. Ligand products (ONTAK etc.) purchase. Eisai paid $200 million to get Ligand’s four marketed oncology products + all the marketing and sales people.
Result: Eisai has not recouped its investment yet from this deal. Most of the human assets came with the deal as LC stated are long gone. There are handful incompetent marketing people at still around to continue their dubious behaviors. Darby James is one of them. Eisai also ended being sued by Keeler.
4. MGI deal: Eisai was duped to pay over the roof premium of $3.9 Billion for MGI. Lusedra was one of the jewels presented to have potential of $400 million a year. Dacogen was as promising as Lusedra.
Result: Guess what, FDA doesn’t like Lusedra and only grant the status of MAC which is not better than others on the market. Now, it is being killed and all the sales reps are being laid off.
Moreover, all the trophy employees from MGI who relocated to New Jersey Institute of Technology have left Eisai and left a huge bill for Eisai to pay.
5. Banzel: Eisai purchased the right to sell from Novartis decade ago. Eisai was hoping to get the indication for general or partial seizures
Result: Indication limited to LGS only. It will be killed soon with the Slyvia Brown’s marketing
.
1. Zonegrame: purchased from Elan for $200 million cash + all the market personnel + sales people
Result: total sales for Eisai from Zonegrame is about $240 million. Eisai ended up with unproductive employees and eventually they after consumed Eisai, they are gone. In addition, Eisai had to settle a lawsuit wit DOJ for Eisai's illegal marketing activities for $11 million. I would say Eisai breaks even on this deal if you only count the capital spending
2. Fragmin: Pfizer sold this dog to Eisai years ago. The Contract states Eisai has to net sale $100 million worth of Fragmin no matter what market condition is. Otherwise, Eisai pays up to $100 million to Pfizer. Fragmin has no had a $100 net sales.
Result: This is a loss for Eisai
3. Ligand products (ONTAK etc.) purchase. Eisai paid $200 million to get Ligand’s four marketed oncology products + all the marketing and sales people.
Result: Eisai has not recouped its investment yet from this deal. Most of the human assets came with the deal as LC stated are long gone. There are handful incompetent marketing people at still around to continue their dubious behaviors. Darby James is one of them. Eisai also ended being sued by Keeler.
4. MGI deal: Eisai was duped to pay over the roof premium of $3.9 Billion for MGI. Lusedra was one of the jewels presented to have potential of $400 million a year. Dacogen was as promising as Lusedra.
Result: Guess what, FDA doesn’t like Lusedra and only grant the status of MAC which is not better than others on the market. Now, it is being killed and all the sales reps are being laid off.
Moreover, all the trophy employees from MGI who relocated to New Jersey Institute of Technology have left Eisai and left a huge bill for Eisai to pay.
5. Banzel: Eisai purchased the right to sell from Novartis decade ago. Eisai was hoping to get the indication for general or partial seizures
Result: Indication limited to LGS only. It will be killed soon with the Slyvia Brown’s marketing